Articles by Our Team

Model Answers’ scientists have diverse backgrounds and a wide range of experience across multiple therapeutic areas. They regularly publish academic work related to pharmacometrics, drug development and clinical practice.

Recent articles by our team:

Evaluation of Concomitant Antiretrovirals and CYP2C9/ CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Bruce Green, Herta Crawls, Thomas N. Kakuda, Simon Vanveggel, Anne Brochot

Impact of Concomitant Antiretrovirals, and CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Bruce Green, Herta Crauwels, Thomas N. Kakuda, Simon Vanveggel, Magda Opsomer, Anne Brochot


Population Pharmacokinetics of Bedaquiline(TMC207), a Novel Antituberculosis Drug

Sarah C. McLeay, Peter Vis, Rolf P. G. van Heeswijk and Bruce Green

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal

J. P. Patel, B. Green, R. K. Patel, J. G. Davies, R. Arya

Population pharmacokinetic characterisation of BAY 81-8973, a full-length recombinant factor VIII:  lessons learned – importance of including samples with factors VIII levels below the quantitation limit.  Haemophilia. 2017

Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Bruce Green and Stephen B Duffull

Dosing in Obesity: A Simple Solution to a Big Problem

P Y Han, S B Duffull, C M J Kirkpatrick and B Green

Development of a dosing strategy for enoxaparin in obese patients

Bruce Green andStephen B. Duffull

The Relationship between Drug Clearance and Body Size

Sarah C. McLeay, Glynn A. Morrish, Carl M. J. Kirkpatrick, Bruce Green

The effects of obesity on drug pharmacokinetics in humans

Glynn A Morrish , Manjunath P Pai & Bruce Green

Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients

Giovanni Di Perri, Bruce Green, Glynn Morrish, Andrew Hill, Gerd Faetkenheuer, Markus Bickel, Yvon van Delft, Michael Kurowski & Thomas Kakuda

A Pharmacokinetic-pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100

N. A. Lack BSc, B. Green MSc, DPh, D. C. Dale MD, G. B. Calandra MD, PhD, H. Lee MD, PhD, R. T. MacFarland PhD, K. Badel BScN, W. C. Liles MD, PhD, G. Bridger PhD

Pharmacokinetic and Pharmacodynamic Modeling of the Relationship Between TAK-442 Exposure and Clinical Outcome In Patients Undergoing Elective Knee Arthroplasty

Fran Stringer, Bart Ploeger, Nolan Wood, Patrick Moneuse, Masaki Kawamura, Stuart Kupfer, Jeff Spaeder, Graham Scott

Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1–11 Years

Sarah C. McLeay , Bruce Green, William Treem, An Thyssen, Erik Mannaert, Holly Kimko

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO

Thomas N. Kakuda PharmD, Anne Brochot MSc, Bruce Green PhD, Steven Nijs MSc, Peter Vis MSc, Magda Opsomer MD, Frank L. Tomaka MD, Richard M. W. Hoetelmans PhD

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar

Frances Stringer, Joost DeJongh PhD, Graham Scott PhD, Meindert Danhof PharmD, PhD

The Impact of Pharmacogenomics Research on Drug Development

Shyh-Yuh Liou, Fran Stringer, Masashi Hirayama

Romiplostim Dose Response in Patients With Immune Thrombocytopenia

Dr J. J. Perez-Ruixo PhD, PharmD, Dr B. Green PhD,Dr S. Doshi BS, Dr Y.-M. Wang PhD,
Dr D. R. Mould PhD, FCP

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

Diane R. Mould , Bruce Green

Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine

J Korell, B Green, A Rae, B Remmerie, A Vermeulen

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone

J Korell, B Green, B Remmerie, A Vermeulen

Optimizing Antipsychotic Patient Management Using Population Pharmacokinetic Models and Point-of-Care Testing

B Green,  J Korell, B Remmerie, A Savitz, A Vermeulen

The Impact of Model-Misspecification on Model Based Personalised Dosing

David A. J. McDougall , Jennifer Martin, E. Geoffrey Playford, Bruce Green

Determination of a suitable voriconazole pharmacokinetic model for personalised dosing

David A. J. McDougall , Jennifer Martin, E. Geoffrey Playford, Bruce Green

Individualized Compared With Conventional Dosing of Enoxaparin

MA Barras, SB Duffull, JJ Atherton, B Green

FDA Clinical Pharmacology Guidance on Paediatrics

General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products

Clinical trial simulations – an essential tool in drug development

Alun Bedding, Graham Scott, Nigel Brayshaw, Louise Leong, Esteban Herrero-Martinez, Michael Looby, Peter Lloyd